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SUMMARY
This open label study examines whether methotrexate (MTX) treatment modulates ex vivo synthesis of interleuldn-1 receptor
antagonist (IL-lra), soluble tumour necrosis factor receptors (sTNFR p55 and p75), interleukin-1/? (IL-1/?), tumour necrosis
factor a (TNF-a), interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) by peripheral blood mononuclear cells
(PBMQ and whether changes reflect clinical response. Significant stimulation of IL-lra and sTNFR p75 as well as inhibition
of IL-8 production of PBMC were associated with clinical improvement observed in patients treated with MTX. When defining
the characteristics of patients at study entry retrospectively in responders and non-responders, a significantly lower ratio of
IL-lra :IL-1/? production before and its increase upon treatment was associated with clinical response in 13 patients compared
to five patients not responding to MTX. In addition, clinical improvement was associated with decreased synthesis of IL-1/?,
TNF-a and IL-8 induced by bacterial lipopolysaccharide, IL-1 a and IL-1/? in PBMC in vitro. These findings suggest that MTX
therapy reverses the inflammatory type of rheumatoid arthritis (RA) blood mononuclear cells by stimulating cytokine inhibitor
production while inhibiting inflammatory cytokine release at the same time. This may explain the powerful anti-inflammatory
properties of low-dose MTX as observed in most RA patients. Pretreatment determination of the IL-lra: IL-1 /? ratio in PBMC
may be predictive with regard to a favourable therapeutic response and therefore may be useful for the selection of RA patients
to be treated with MTX.
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WEEKLY low-dose treatment with methotrexate (MTX)
is highly effective in rheumatoid arthritis (RA) [1-4],
and has supplanted classic second-line drugs such as
injectable gold because of its superior efficacy/toxicity
trade-offs [5]. Its mode of action in RA, however, is
poorly understood. Most studies of immune function in
RA patients treated with MTX show only marginal
effects 6n humoral and cellular immune responses [6].
The rapid clinical remission as observed in the majority
of RA patients upon MTX treatment and the fast flare
of disease after drug discontinuation [7] suggest that
the mechanism of action of MTX in RA might be more
anti-inflammatory than immunosuppressive. As shown
in recent studies MTX appears to interfere directly
with the action of pro-inflammatory cytokines such as
interleukin-1 (IL-1) [8-10]. MTX also inhibits IL-1
production by macrophages in rat adjuvant arthritis
[11, 12], interleukin-8 (IL-8) production by peripheral
blood mononuclear cells (PBMQ [13], leukotriene B4
synthesis in neutrophils [14], and decreases selectively
synovial collagenase gene expression [15]. Recent data
suggest that MTX increases the release of adcnosine
by connective tissue cells, which might inhibit neutro-
phil adherence to endothelial cells and fibroblasts [16].
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The effect of MTX on cytokine synthesis is particu-
larly important in RA, since mediators like IL-1 and
tumour necrosis factor a (TNF-a) play a key role in the
perpetuation of synovial inflammation [17], but there is
no information whether this drug may also affect
cytokine inhibitor production. Although physiological
cytokine inhibitors such as interleukin-1 receptor ant-
agonist (IL-lra) and soluble TNF-a receptors are re-
leased during the inflammatory synovial process
[18-20], their action is obviously insufficient to prevent
the pathophysiological events mediated by IL-1 and
TNF-a. We have studied the effects of low-dose MTX
treatment in RA patients by ex vivo assessment of its
effects on cytokine inhibitor and inflammatory cy-
tokine production by PBMC and correlated the results
with the clinical course of the disease.
PATIENTS AND METHODS
Patients
Eighteen patients with active RA were treated for up
to 24 weeks with weekly intramuscular injections of
15 mg MTX. Active RA was defined by fulfilment of at
least three of the following four criteria: six or more
joints tender or painful on motion, three or more
swollen joints, erythrocyte sedimentation rate (ESR)
> 28 mm/h and morning stiffness > 45 min in duration.
MTX and dosage of concomitant non-steroidal anti-
inflammatory drugs (NSAIDs) and steroids (<7.5 mg
prednisone/day) were kept constant during the whole
study. Clinical assessment was performed before, and
© 1995 British Society for Rheumatology
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6, 12 and 24 weeks after starting MTX therapy.
Laboratory assessment before and during treatment
included ESR, routine haematology, crythrocyte folinic
acid, serum transaminases, alkaline phosphatase and
creatinine.
After 12 weeks of treatment the patients were divided
retrospectively into two groups, 'responders' and 'non-
responders', according to a composite activity index
which was previously described [21]. The original index
was modified in that in our study 'responders' had to
fulfil the criteria of a > 50% improvement from base-
line for morning stiffness, Westergreen ESR, tender-
joint and swollen-joint scores (60 and 58 joints,
respectively, hips not assessed for swelling; graded
0-3), and the patient's and physician's assessment of
disease severity [on a five-point scale, ranging from 1
(symptom-free) to 5 (very severe)]. Patients with
deterioration of disease upon treatment were defined as
'non-responders'.
Cells
Venous blood was drawn from RA patients 6-10 h
after the last intramuscular injection of MTX and
blood mononuclcar cells were isolated immediately by
Ficoll-Hypaque fractionation [22] afterwards. The cells
were washed three times in PBS and resuspended in
culture medium (106 cells/ml). Viability was tested by
trypan blue exclusion (87-96% viable cells). The num-
ber of monocytes was determined by differential count-
ing after staining for non-specific esterase [23].
Monocyte counts in PBMC of patients ranged between
14 and 46% interindividually before treatment and no
statistically significant intra- and intergroup as well as
intraindividual differences were observed throughout
the study. Based on this observation, there was no need
for improving the cytokine values in cell culture super-
natants with reference to the percentage of monocytes
among PBMC. Cells (2 x 10*) in 0.2 ml RPMI 1640
supplemented with lOOIU/ml penicillin/streptomycin
(Gibco, Basel, Switzerland), and 1% pasteurized
plasma protein solution (5% PPL SRK, Swiss Red
Cross) were incubated with or without different stimuli
in flat-bottom microtitre plates (Nunc, Denmark) in a
humidified atmosphere of 5% CO2 at 37°C for 48 h.
Cell culture supernatants were collected and stored at
-70°C until use.
Cytokine assays
Interleukin-1 was determined by IL-10 specific and
two-site directed enzyme-linked immunoassay (ELISA)
with an exclusion limit of 8 pg/ml and an inter-assay
variability of 5-27% [24]. Levels of IL-lra were
measured by a specific ELISA using a newly developed
monoclonal antibody and a rabbit antiserum with a
lower detection limit of 20 pg/ml [25]. TNF-a was
assessed by a specific ELISA (lower detection limit
20 pg/ml) method as previously described [26] and
soluble TNF-a receptors (p55 and p75) were measured
by an enzyme-linked binding assay with a sensitivity of
100 pg/ml [27]. The TNF-a assay did not interfere with
the addition of high concentrations of recombinant
soluble tumour necrosis factor receptors (sTNFR) (p55
and p75) to medium containing known amounts of
TNF-a. The determination of sTNFR (p55 and p75)
was not influenced by up to 10 ng/ml of TNF-a in the
same cell culture medium. For the determination of
IL-8 a solid phase double-ligand ELISA method with
a lower detection limit of 50 pg/ml was used [28].
MCP-1 was assessed by a highly specific ELISA which
detects MCP-1 levels above 40 pg/ml [29]. All ELISAs
used had a 100% recovery after addition of definite
amounts of recombinant cytokines to culture media.
All cytokine values were determined twice from duplic-
ates, and the mean of four separate determinations
from each patient sample at a given time is presented.
Reagents
Interleukin-la and interleukin-1/? (kind gift of Dr J.
Vosbeck, Ciba-Geigy, Basel, Switzerland) were used at
10 ng/ml and LPS from Escherichia coli (Gibco Cult,
Basel, Switzerland) at 100 ng/ml. These concentrations
were shown to have maximum effects on either
cytokine and cytokine inhibitor production of PBMC
in prior dose-response experiments. Reagents for
the TNF-a ELISA were kindly provided by F.
Hoffmann-La Roche (Basel, Switzerland). All cytokine
preparations and other reagents were free of bacterial
lipopolysaccharide (LPS) as assessed by a negative
limulus assay.
Statistics
Intragroup comparisons were performed using the
Student's /-test (responders) and the Wilcoxon ranked-
sum test (non-responders). Intergroup differences were
assessed by the Wilcoxon ranked-sum test. Results
were considered statistically significant at P < 0.05.
RESULTS
Characteristics of patients at study entry
Based on a composite activity index for evaluation of
the efficacy of second-line drugs [21], 13 patients
(72.2%) fulfilled the criteria of 'responders' whereas
only five patients (27.8%) had to be classified as
TABLE I
Characteristics of patients at study entry
Age(yr)
Males/females
Duration of RA (yr)
ESR (mm/h)
Positive rheumatoid factor
Swollen-joint count (0-58)
Tender-joint count (0-60)
Morning stiffness (min)
Erosive disease (% of patients)
Concurrent therapy
NSAIDs (number of patients)
NSAIDs + prednisone
(<10 rag/day)
Responders
(n = 13)
57.4 ± 17.2*
1/12
3.8 ± 4.2
6 4 ± 3 4
12 (92)t
17.8 ±6.4
23.7 ± 8.9
127 ± 5 9
77
13 (100)
1 (8)
Non-
responders
(n-5)
57.8 ±16
1/4
6.7 ± 9.3
69±34
4(80)
15.6 ±4.6
20.6 ±5.5
144 ± 100
60
5(100)
1 (20)
•Values are given as the mean ± S.D.
tPercentage in parentheses.
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FIG. 1.—Parameters of rheumatoid arthritis disease activity before and during 24 weeks of methotrexate (MTX) treatment in responders
( • ; n = 13) and non-responders (O; n =• 5). The tender-joint counts (A), the swollen-joint count (B), duration of morning stiffness in minutes
(Q and the erythrocyte sedimentation rate (mm/h) (D) were determined before and, 6, 12 and 24 weeks after starting MTX treatment. Values
of individual patients and the corresponding means of responders and non-responders are shown. *P <0.05, **P < 0.025, ***p < 0.01,
*P < 0.005, + + P < 0.0005, + + +/> < 0.0001 (refers to intragroup comparisons).
'non-responders' after a 12-week treatment with low-
dose MTX. Thus, the classification of 'responders'
and 'non-responders' was performed retrospectively.
Table I shows that the clinical entry variables did not
differ significantly between the two outcome groups.
Clinical parameters of disease activity before and during
MTX treatment
Figure 1 shows the changes of clinical parameters of
disease activity like tender- and swollen-joint score,
duration of morning stiffness and the ESR before and
during 24 weeks of MTX treatment. Responding
patients exhibited a significant reduction of the number
of tender and swollen joints, duration of morning
stiffness and the ESR (P < 0.025-0.005) already after
6 weeks of treatment. In this group of patients further
amelioration of disease activity was observed after 12
and 24 weeks of MTX therapy (P < 0.0005-0.0001). In
contrast, non-responding patients exhibited at least
increasing swollen-joint counts after 12 and 24 weeks
of treatment compared to baseline values (P < 0.05).
Pretreatment cytokine and cytokine inhibitor production
of PBMC
As shown in Table II constitutive IL-l/J production
by PBMC from 'responders' before treatment was
significantly higher (P < 0.025) and IL-1 ra release
slightly lower (P < 0.05) compared with 'non-
responders'. Consequently, RA patients responding to
treatment exhibited a lower IL-lra: IL-1/? ratio than
TABLE D
Pretreatraent concentrations of IL-l/J, IL-lra, TNFa, sTNFR (p55 and p75), 1L-8, MCP-I and the ratio of IL-lra: IL-1/? levels in culture
supematants of unstimulated PBMC of responding, non-responding RA patients and healthy control individuals
Group (n)
Responding (13)
Mean ± s.D.
Range
Non -responding
Mean ± S.D.
Range
Healthy control
Mean ± S.D.
Range
IL-IP
(ng/ml)
0.16 ±0.18**
0.01-0.51
(5)
0.03 ± 0.02
0.01-0.06
individuals (6)
0.009 ±0.01
< 0.008-0.02
IL-lra
(ng/ml)
3.37 ± 2.42*
0.50-7.30
6.48 ± 3.42
2.10-11.70
2.94 ± 2.05
0.86-5.88
IL-lra:IL-10
52 ± 4 3 * "
2-117
466 ±455
88-1170
>294
TNF-a
(ng/ml)
<0.02
0.04 ± 0.09
< 0.02-0.2
<0.02
p55
(ng/ml)
0.54 ±0.20
0.22-0.95
0.46 ± 0.20
0.25-0.70
0.36 ± 0.09
0.22-0.42
p75
(ng/ml)
0.59 ±0.51
0.18-1.99
0.42 ±0.15
0.17-0.55
1.15 ±0.89
0.28-2.87
IL-8
(ng/ml)
13.0 ±13.0
0.6-43.6
9 ±8.2
1.2-19.7
2.03 ±1.18
0.4-3.6
MCP-1
(ng/ml)
0.25 ± 0.65
< 0.04-2.43
<0.04
<0.04
*P = 0.05; ••/» < 0.025; ***P < 0.0025; ranked sum test (comparison of R vs NR).
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Fio. 2.—Spontaneous interleukin-1/7 (IL-1/?) and interleukin-1 re-
ceptor antagonist (IL-lra) production of PBMC and their ratio
during 24 weeks of MTX treatment. Peripheral blood mononuclear
cells (2 x 103) of rheumatoid arthritis patients (n = 18) were obtained
before, and after 6, 12 and 24 weeks of methotrexate treatment and
cultured in quadruplicates for 2 days in medium containing 1%
plasma protein solution. IL-1/? (A) and IL-lra (B) production of
responding ( • ; n - 13) and non-responding (O; " *• 5) patients was
determined in cell culture supernatants. Ratios of individual IL-
lra:IL-I/? production were calculated (C). Values of individual
patients and their corresponding means are shown. */"<0.05,
*P <0.02, ••/• < 0.025, + + P <0.01 (refers to intragroup compar-
isons).
their non-responding counterparts (P < 0.0025). In
contrast, pretreatment levels of constitutive IL-8,
MCP-1, sTNFR p55 and p75 production did not differ
significantly between the two patient groups and except
for one non-responding patient TNF-a was not de-
tectable. In contrast to RA patients, very small
amounts of spontaneous IL-1/? production by PBMC
were detected only in 50% of healthy individuals.
Spontaneous cytokine and cytokine inhibitor production
of PBMC during MTX treatment
Figures 2-4 show the differences between patients
with and without clinical improvement after 6, 12 and
24 weeks of treatment. There was no significant change
0.1-1
12
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24
FKJ. 3.—Spontaneous tumour necrosis factor alpha (TNF-a), soluble
tumour necrosis factor receptors (sTNFR) p55 and p75 production
of peripheral blood mononuclear cells (PBMC) during 24 weeks of
methotrexate (MTX) treatment. PBMC (2 x 10*) of rheumatoid
arthritis patients (n - 18) were obtained before, and after 6, 12 and
24 weeks of MTX treatment and cultured in quadruplicates for 2
days in medium containing 1 % plasma protein solution. TNF-a (A),
sTNFR p55 (B), and sTNFR p75 ( Q production of responding
( • ; n " 13) and non-responding (O; " = 5) patients was determined
in cell culture supernatants. Values of individual patients and their
corresponding means are shown. *P <0.05 (refers to intragroup
comparisons).
of constitutive IL-1/? release from PBMC of 'respond-
ers', whereas cells from 'non-responders' exhibited
enhanced IL-1/? production during treatment (P < 0.05
after 6, P < 0.05 after 12 and P < 0.02 after 24 weeks)
(Fig. 2A). In contrast, we found elevated levels of
IL-lra in responding patients after 6 (P<0.05), 12
(P < 0.05) and 24 weeks (P < 0.05) but markedly
decreased levels (week 12, P < 0.01) in non-responding
patients (Fig. 2B). Calculation of the IL-lra:IL-10
ratio for each RA patient allowed us to get information
about changes of the inflammatory type of blood
mononuclear cells during MTX treatment. The mean
ratio of the responder group increased concomitantly
with clinical improvement after 6 (P <0.05), 12
(P < 0.025) and 24 (P < 0.05) weeks of treatment. In
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Fio. 4.—Spontaneous interleukin-8 (IL-8) and monocyte chemoat-
traclant protein-1 (MCP-1) production of peripheral blood mono-
nuclear cells (PBMC) during 24 weeks of methotrexate (MTX)
treatment. PBMC (2 x 103) of rheumatoid arthritis patients (n => 16)
were obtained before, and after 6, 12 and 24 weeks of MTX
treatment and cultured in quadruplicates for 2 days in medium
containing 1% plasma protein solution. IL-8 (A) and MCP-1 (B)
production of responding ( # ; n — 13) and non-responding (O;
n = 5) patients was determined in cell culture supernatants. Values
of individual patients and their corresponding means are shown.
*P < 0.05, **P < 0.025 (refers to intragroup comparisons).
contrast, the higher baseline ratio of non-responders
before treatment declined over 12 weeks (P < 0.01) and
remained at a low level (P <0.0\) after 24 weeks
(Fig. 2C). Levels of TNF-ot and sTNFR p55 did not
vary significantly during MTX treatment, whereas
sTNFR p75 was slightly upregulated in clinical
responders (P < 0.05 at week 24) (Fig. 3A-Q. PBMC
of RA patients produced considerable amounts of IL-8
and in a few cases low amounts of MCP-1. IL-8 release
from PBMC of clinical responders was downregulated
after 6 (P < 0.025) and 24 weeks (P < 0.025), whereas
in non-responders IL-8 was upregulated (P < 0.05)
(Fig. 4A, B).
In vitro stimulated cytokine production of PBMC
obtained during MTX treatment
Upon in vitro stimulation with IL-la, production of
IL-l/f and IL-8 by PBMC of responding patients
declined after 12 or 24 weeks of in vivo MTX treatment
(P < 0.05; P < 0.025; Fig. 5A, B), whereas synthesis of
TNF-a, soluble TNF-a receptors, IL-lra and of MCP-1
were not affected (data not shown). A similar down-
regulation of IL-8 but also of TNF-a was observed
after in vitro stimulation of PBMC with IL-1/?
(P < 0.025 and P < 0.05 after 24 weeks) (Fig. 6A, B).
In contrast, cells from non-responders exhibited an
enhanced production of TNF-a after 24 weeks
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Fio. 5.—In vitro interleukin-la (IL-la^stimulated cytokine pro-
duction of peripheral blood mononudear cells (PBMC) during 24
weeks of methotrexate treatment. PBMC (2 x 103) of rheumatoid
arthritis patients (n = 18) were obtained before, after 6, 12 and 24
weeks of MTX treatment and cultured in quadruplicates for 2 days
in medium containing IL-la (lOng/ml) and 1% plasma protein
solution. IL-l/f (A) and IL-8 (B) production of responding
( • ; n " 13) and non-responding (O; " — 5) patients was determined
in cell culture supernatants. Values of individual patients and their
corresponding means are shown. *P < 0.05, **P < 0.025 (refers to
intragroup comparisons).
(P < 0.01; Fig. 6A). After stimulation with LPS PBMC
of 'responders' showed a significant decline of IL-8
production after 24 weeks of MTX treatment (Fig. 7A;
P <0.01), whereas IL-8 release in non-responders re-
mained unaffected. The release of IL-lra, sTNFR and
MCP-1 was not modulated under these conditions
(data not shown). Cytokine levels after 6 weeks of
treatment are not shown, because they did not differ
from baseline values.
DISCUSSION
First, our study shows that conventional clinical and
laboratory criteria alone are insufficient to discern
whether a patient will respond or not respond to
low-dose MTX treatment. We found that a favourable
therapeutic response of our patients was associated in
84.6% with a pretreatment ratio of constitutive IL-
lra : IL-1 p production by PBMC of lower than 100,
whereas a pretreatment ratio of higher than 100 was
observed in 80% of the non-responding patients. Based
on this finding, we assume that a high inflammatory
activity of monocytes as reflected by high IL-1/? and
relatively low IL-lra production may give a hint to a
more favourable response to MTX treatment in the
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FIG. 6.—In vitro interleukin-1/f (IL-l/7)-stimulated cytokine pro-
duction of peripheral blood mononuckar cells (PBMC) during 24
week* of methotrcxate (MTX) treatment. PBMC (2 x 103) of rheum-
atoid arthritis patients (n = 18) were obtained before, and after 6, 12
and 24 weeks of MTX treatment and cultured in quadruplicates for
2 days in medium containing 1L-1/J (lOng/ml) and 1% plasma
protein solution. Tumour necrosis factor a (A) and interleukin-8 (B)
production of responding ( • ; n «- 13) and non-responding (O;
n =» 5) patients was determined in cell culture supernatants. Values
of individual patients and their corresponding means are shown.
*P <0.05, **P < 0.025, *+P <0.01 (refers to intragroup compar-
isons).
majority of RA patients. In contrast, pretreatment
levels of TNF-<x, sTNFR, IL-8 and MCP-1 production
of PBMC were found to be irrelevant for prediction of
treatment outcome. This is the first study that suggests
IL-lra and IL-1/? production by blood monocytes as a
possibly useful prognostic marker for the therapeutic
response of RA patients to MTX.
The second finding in our study is that clinical
improvement is accompanied by stimulation of spon-
taneous IL-lra and sTNFR p75 production by PBMC.
A significant increase of IL-lra in most patients to-
gether with unchanged or decreased IL-1/? release from
PBMC resulted in a 4-14-fold increase of the IL-
lra : IL-1 /? ratio after 6-24 weeks of MTX treatment in
clinically improved patients. In clinical nonresponders
this ratio markedly declined during treatment. Though
all responding patients showed most impressive clinical
improvement 12 weeks after starting MTX treatment,
disease activity significantly declined already after 6
weeks. Accordingly, the 6-week values at least of
IL-lra and IL-8 showed a small but significant differ-
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FIG. 7.—In vitro bacterial lipopolysaccharide (LPS)-stimulated inter-
leukin-8 (IL-8) production of peripheral blood mononudear cells
(PBMC) during 24 weeks of methotrexate (MTX) treatment. PBMC
(2 x 101) of rheumatoid arthritis patients (n = 18) were obtained
before, and after 6, 12 and 24 weeks of MTX treatment and cultured
in quadruplicates for 2 days in medium containing LPS (100 ng/ml)
and 1% plasma protein solution. IL-8 production of responding ( • ;
n » 13) and non-responding (O; " — 5) patients was determined in
cell culture supernatants. Values of individual patients and their
corresponding means are shown. */><0.01 (refers to intragroup
comparisons).
ence from baseline. The anti-inflammatory effect ob-
served clinically fits well with the 100-fold excess of
IL-lra which is needed in vitro and in vivo to effectively
antagonize IL-1-mediated activation of T-cells, fibro-
blasts and chondrocytes [17, 30]. An excess of IL-lra
production most likely occurs in active RA, as evid-
enced by the very high levels of this protein found in
the synovial fluids of RA patients compared to very
low amounts of IL-1)? [25]. Why is there nevertheless
on-going synovitis in this patients? This question is still
unsolved.
It is conceivable that IL-lra production in rheumat-
oid synovial tissue may not be in sufficient excess to
inhibit the proinflammatory effects of locally produced
IL-1. From the therapeutic view, therefore, an even
higher excess of IL-lra over IL-1 production seems
warranted. This could be achieved either by IL-lra
stimulation as shown in this study or by diminishing
IL-1 production as found recently in synovial fluid of
RA patients undergoing MTX treatment [31]. Another
explanation for insufficient anti-inflammatory action of
endogenously produced IL-1 ra in rheumatoid synovitis
may be that other cytokines such as TNF-a may be
more important in the initiation and perpetuation of
the disease process [32]. In this study we also found a
late upregulation of sTNFR p75 synthesis of PBMC
after 24 weeks of treatment which was associated with
clinical improvement. This may indicate that for long-
term anti-inflammatory regulation of the cytokine net-
work by MTX, beside IL-lra stimulation, enhanced
sTNFR synthesis may be also important. We further
presume that downregulation of constitutive
chemokine release from PBMC of clinical responders is
most likely the consequence of an increased inhibition
of IL-1-mediated monocyte activation due to enhanced
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IL-lra. The downregulation of IL-8 in the course of
MTX treatment and its coincidence with enhanced cyto-
kine inhibitor production supports this assumption.
The upregulation of sTNFR p75 without affecting
sTNFR p55 contrasts with a previous study [33] show-
ing reduced sTNFR p55 levels in sera of RA patients
responding to MTX treatment. Because cytokine levels
measured in serum represent the net result of pro-
duction and clearance within the circulation without
giving information about the source of production, we
believe that examination of cytokine regulation on the
cellular level as surveyed in this study will give better
insight into the effects of any therapeutic intervention
on the unbalanced cytokine network in RA. Because
sTNFR in serum behave like acute phase proteins as
shown by elevated levels according to inflammatory
disease activity in RA and systemic lupus erythemato-
sus [33, 34] as well as after surgery [35], we think that
changes of serum sTNFR levels might merely reflect
epiphenomena.
Furthermore, our study shows that in clinical res-
ponders MTX treatment in vivo reduced IL-1 and
LPS-induced cytokine release from PBMC in vitro.
This was documented by the marked downregulation
of PBMC capacity to synthesize IL-10, TNF-a and
IL-8 after corresponding stimulation. In contrast to
sTNFR p75, sTNFR p55 production of PBMC was
not regulated by either systemic MTX treatment
in vivo or cytokine or LPS mediated stimulation
in vitro. The expression and shedding of both sTNFR
may be indeed distinctly regulated [27, 36]. Interest-
ingly, in a recent study, pretreatment with ibuprofen
in human experimental endotoxinaemia increased and
prolonged concentrations of TNF-a and sTNFR
p75 in the circulation without affecting p55 levels [37].
It is therefore possible that concomitant NSAID
therapy in all our patients may be responsible for
the finding of a distinct regulation of p55 and p75
sTNFR.
In conclusion, these results indicate that MTX treat-
ment clearly affects cytokine inhibitor and cytokine
production of PBMC which may explain its rapid and
long-lasting anti-inflammatory effects when adminis-
tered continuously to RA patients. However, changes
of cytokine profiles observed in this study may occur
as the final common pathway of all therapies and are
not necessarily specific for MTX. Although not meas-
uring whole IL-1 (a + /J), our results give a hint that
beside clinical parameters a low ratio of IL-lra:IL-1/J
production of PBMC might be an additional help to
predict favourable clinical response to MTX treatment.
Further studies with larger numbers of patients are
needed to decide definitely whether pretreatment
screening for IL-lra and IL-l/J production of PBMC
should be generally recommended before starting
therapy with MTX or other second-line drugs in RA.
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